FDA warns Liveyon about selling unapproved stem-cell products that pose a risk to consumers
The Food and Drug Administration warned Livyeon for selling unapproved products derived from cord blood. It also also said “deviations” from best manufacturing practices could put consumers at risk.
View original article
Contributor: Laurie McGinley
